Publicaciones en colaboración con investigadores/as de Medical University of Vienna (75)

2022

  1. 6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 13, pp. 1366-1377

  2. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022

    Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 6, pp. 1855-1865

  3. Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry

    Circulation. Cardiovascular interventions, Vol. 15, Núm. 3, pp. e011302

  4. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  5. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

    Annals of Oncology, Vol. 33, Núm. 3, pp. 259-275

  6. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2039-2051

  7. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  8. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1

  9. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024

  10. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 242-251

  11. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1953-1963

  12. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1986-1998.e2